Cardiovascular research · 2018
Identification of cardiac long non-coding RNA profile in human dilated cardiomyopathy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huaping, Chen Chen, Fan Jiahui, Yin Zhongwei, Ni Li, Cianflone Katherine, Wang Yan, Wang Dao Wen
Аннотация
AIMS: Dilated cardiomyopathy (DCM) induced chronic heart failure is a life-threatening disease worldwide. Long non-coding RNAs (lncRNAs) are potential new therapeutic targets and may provide new pathophysiological mechanisms for development of DCM.
METHODS AND RESULTS: Microarray assays in 14 DCM and 10 control human heart samples identified 313 significantly differentially expressed lncRNAs. SiRNAs were used to explore the potential function of specific lncRNAs (RP11-544D21.2 and XLOC_014288) in human cardiac myocytes, human cardiac fibroblasts and human cardiac microvascular endothelial cells, respectively. RNA-seq and pathway analyses revealed the function of lncRNA RP11-544D21.2 and XLOC_014288 in three heart cells. Furthermore, impaired tube formation and migration were observed in si-RP11-544D21.2-treated endothelial cells. Moreover, TAF10 was predicted and verified to be one of the causes of some up-regulated lncRNAs. Then, we found that the left ventricular ejection fraction correlated with these changed lncRNAs.
CONCLUSIONS: This study provides a comparison of human cardiac lncRNA profiles in control and DCM. It illustrates the function and complex roles of the differentially expressed lncRNAs in different cell types in the heart, which may lead to new insights into the mechanisms and treatment strategies for DCM in the future.
METHODS AND RESULTS: Microarray assays in 14 DCM and 10 control human heart samples identified 313 significantly differentially expressed lncRNAs. SiRNAs were used to explore the potential function of specific lncRNAs (RP11-544D21.2 and XLOC_014288) in human cardiac myocytes, human cardiac fibroblasts and human cardiac microvascular endothelial cells, respectively. RNA-seq and pathway analyses revealed the function of lncRNA RP11-544D21.2 and XLOC_014288 in three heart cells. Furthermore, impaired tube formation and migration were observed in si-RP11-544D21.2-treated endothelial cells. Moreover, TAF10 was predicted and verified to be one of the causes of some up-regulated lncRNAs. Then, we found that the left ventricular ejection fraction correlated with these changed lncRNAs.
CONCLUSIONS: This study provides a comparison of human cardiac lncRNA profiles in control and DCM. It illustrates the function and complex roles of the differentially expressed lncRNAs in different cell types in the heart, which may lead to new insights into the mechanisms and treatment strategies for DCM in the future.
Предметные рубрики MeSH
AdultAgedCardiomyopathy, DilatedCase-Control StudiesCell MovementCell ProliferationCells, CulturedEndothelial CellsFemaleFibroblastsGene Expression ProfilingGenetic MarkersGenetic Predisposition to DiseaseHumansMaleMiddle AgedMyocytes, CardiacNeovascularization, PhysiologicOligonucleotide Array Sequence AnalysisPhenotypeRNA, Long NoncodingStroke VolumeVentricular Function, Left